For example, TET2-specific mutations are observed in 15% of patients with myeloid cancers, including MDS and AML (Delhommeau et al. 2009), and 50% of CML patients (Fig. 4; Kosmider et al. 2009). This evidence concerns the gene TET2 and myelodysplastic syndrome.